It is common knowledge that men with metastatic castration-resistant prostate cancer (CRPC) don’t all have the same disease. There are many different types or flavors of prostate cancer.
These differences are involved in the genetic structure of the cancer cell its self. Some prostate cancers have mutations in the DNA repair genes (genes whose job is to repair other gene mutations). It has been shown that prostate cancer that have these mutations are more likely to respond to the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib. (Currently olaparib is FDA approved for certain types of advanced ovarian cancers.)